Galderma agrees to acquire ZO Skin Health
Source publication date
Site published
ZO's retinol-led daily care complements Alastin's procedure-related skincare. Closing is expected in Q4 2026 or early 2027, subject to approvals.
Summary
The announced enterprise value is USD 1.5 billion.
Editorial view
Analysis: watch competition linking home skincare with aesthetic procedures.
Evidence and limitations
Not a completed acquisition or proof of anti-aging efficacy or lifespan extension.